Nuwellis marks first commercial sale of quelimmune™ therapy to cincinnati children's

Minneapolis, july 17, 2024 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, is proud to announce its first commercial sale of quelimmune™, a novel therapy developed by seastar medical holding corporation for pediatric patients suffering from an uncontrolled inflammatory response triggered by their immune systems, to cincinnati children's. we believe this milestone marks a significant advancement in pediatric critical care and underscores nuwellis' commitment to revolutionizing pediatric patient outcomes.
NUWE Ratings Summary
NUWE Quant Ranking